Tivozanib Publications & Presentations | AVEO Oncology

Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

February 16, 2013
PresentationTivozanib

ASCO GU 2013: Subgroup analyses of a Phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC)

February 16, 2013
PresentationTivozanib

ASCO GU 2013: Treatment benefit of tivozanib hydrochloride vs sorafenib on health-related quality of life among patients with advanced/metastatic renal cell carcinoma (mRCC): TIVO-1 study results

February 16, 2013
PresentationTivozanib

ASCO GU 2013: Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride

February 16, 2013
PresentationTivozanib

ASCO GU 2013: Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib

February 16, 2013
PresentationTivozanib

ASCO GU 2013: Overall survival results from a Phase III study of tivozanib hydrochloride vs sorafenib in patients with renal cell carcinoma

October 1, 2012
PresentationTivozanib

ESMO 2012: Detailed comparison of the safety of tivozanib hydrochloride versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase III trial

1 … 6 7 8 9 10 … 12

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.